Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Anesthesiol. Mar 27, 2014; 3(1): 61-70
Published online Mar 27, 2014. doi: 10.5313/wja.v3.i1.61
Published online Mar 27, 2014. doi: 10.5313/wja.v3.i1.61
Opioid misuse in Canada and critical appraisal of aberrant behavior screening tools
Grace EC Frankel, Howard Intrater, Malcolm Doupe, Michael Namaka, Faculty of Pharmacy, University of Manitoba, Manitoba R3E 0T5, Canada
Author contributions: Frankel GEC, Intrater H, Doupe M and Namaka M solely contributed to this paper.
Correspondence to: Michael Namaka, PhD, Associate Professor, Faculty of Pharmacy, University of Manitoba, Room 319, Apotex Centre, 750 McDermot Ave. Winnipeg, Manitoba R3E 0T5, Canada. mike.namaka@umanitoba.ca
Telephone: +1-204-4748380 Fax: +1-204-4747617
Received: October 30, 2013
Revised: January 15, 2014
Accepted: February 16, 2014
Published online: March 27, 2014
Processing time: 132 Days and 5.1 Hours
Revised: January 15, 2014
Accepted: February 16, 2014
Published online: March 27, 2014
Processing time: 132 Days and 5.1 Hours
Core Tip
Core tip: With the increase in opioid prescribing in Canada, prescription opioid misuse is a growing concern from a health care, financial and safety standpoint. Definitions regarding opioid misuse and covariate risk factors predictive of opioid misuse are controversial. The currently available risk assessment tools used to predict or detect opioid misuse vary in terms of sensitivity, specificity, quality, reproducibility and have been validated in very limited patient populations. There is a clear need for the development of a generalizable risk assessment tool to assess for prescription opioid misuse.